MARKET

SQZ

SQZ

SQZ Biotechnologies Co
NYSE

Real-time Quotes | Nasdaq Last Sale

26.22
-1.02
-3.74%
Opening 10:39 01/20 EST
OPEN
26.71
PREV CLOSE
27.24
HIGH
27.22
LOW
26.00
VOLUME
5.50K
TURNOVER
--
52 WEEK HIGH
36.49
52 WEEK LOW
12.98
MARKET CAP
628.55M
P/E (TTM)
-16.2373
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Biotech IPO Frenzy Brings in 3 Stocks to Buy
2020 was a year to remember, for so many reasons, but there is one reason that might not be obvious: it was the year of the IPO. The crazy corona crisis year didn’t just bring us social distancing and mass mask mandates, it also brought us a huge number of...
TipRanks · 12/31/2020 20:42
SQZ Biotech to Present at Evercore ISI Virtual HealthCONx Conference
SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief executive officer of SQZ, will be participating in a fireside chat at the Evercore ISI Virtual HealthCONx Conference on Wednesday, December 2, 2020 at 10:55 am EST.
Business Wire · 11/23/2020 11:45
SQZ Biotech to Present at Evercore ISI Virtual HealthCONx Conference
SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief executive officer of SQZ, will be participating in a fireside chat at the Evercore ISI Virtual ...
Business Wire · 11/23/2020 11:45
The Week Ahead In Biotech: Moderna Vaccine And Roche, Revance, Rhythm, Liquidia FDA Updates
Biotech stocks came under pressure in the week ended Nov. 20, reversing course from the previous week.
Benzinga · 11/22/2020 12:22
The Daily Biotech Pulse:Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 17)
Benzinga · 11/18/2020 12:29
Lexicon Pharmaceuticals, Zomedica Pharmaceuticals leads healthcare gainers; Brainstorm Cell Therapeutics, GoodRx Holdings among losers
Gainers: Lexicon Pharmaceuticals (LXRX) +45%, Zomedica Pharmaceuticals (ZOM) +33%, Miragen Therapeutics (MGEN) +17%, SQZ Biotechnologies (SQZ) +15%, PLx Pharma (PLXP) +13%.Losers: Brainstorm Cell Therapeutics (BCLI) -67%, GoodRx Holdings (GDRX) -19%, iBio (IBIO) -18%, Co-Diagnostics (CODX) -17%, Alterity Therapeutics (ATHE) -16%.
Seekingalpha · 11/17/2020 16:06
SQZ Biotech to Present at November Virtual Investor Conferences
Business Wire · 11/12/2020 11:45
SQZ Biotech to Present at November Virtual Investor Conferences
SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief executive officer of SQZ, and additional management will participate in the following upcoming virtual investor conferences:
Business Wire · 11/12/2020 11:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SQZ. Analyze the recent business situations of SQZ Biotechnologies Co through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SQZ stock price target is 38.33 with a high estimate of 40.00 and a low estimate of 37.00.
EPS
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 23.97M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.83%
Pharmaceuticals & Medical Research
+0.52%
Key Executives
Chairman/Director
Amy Schulman
Chief Executive Officer/Co-Founder/Director
Armon Sharei
Co-Founder/Director
Klavs Jensen
Chief Financial Officer/Primary Contact
Teri Loxam
Chief Scientific Officer
Howard Bernstein
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SQZ
SQZ Biotechnologies Company is a clinical-stage biotechnology company. The Company is developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. It uses its technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. Its SQZ Antigen Presenting Cells (SQZ APC) platform is in a Phase I trial in highly immunogenic (HPV) plus tumors. It is also developing SQZ Activating Antigen Carriers (SQZ AAC) and SQZ Tolerizing Antigen Carriers (SQZ TAC). Its SQZ APC platform is focused on generating robust (cluster of differentiation 8 (CD8) plus T cell responses. Its lead product candidate, SQZ- peripheral blood mononuclear cells (PBMC)-HPV, from its SQZ APC platform, is a targeted cancer vaccine that has been designed to generate antigen-specific CD8 plus T cell responses to attack HPV plus tumors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of SQZ Biotechnologies Co stock information, including NYSE:SQZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SQZ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SQZ stock methods without spending real money on the virtual paper trading platform.